U.S. President Donald Trump has signed an executive order to create a strategic reserve of active pharmaceutical ingredients (APIs) for 26 essential medicines. This move is part of a broader effort to reduce U.S. dependence on foreign supply chains, particularly from countries like China and India. The new reserve is intended to ensure a stable supply of critical medicines in case of future supply chain disruptions.
The order also directs the Department of Homeland Security and the Department of Health and Human Services to work with U.S. manufacturers to increase domestic production of these essential medicines. The measure is aimed at enhancing the resilience of the U.S. healthcare system and reducing its vulnerability to geopolitical tensions and global supply chain shocks.